Precise Robotically IMplanted Brain-Computer InterfacE

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22-75
SponsorNeuralink Corp

About this trial

The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.

Eligibility criteria

Qualifiers

Severe quadriplegia (tetraplegia) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) for at least 1 year without improvement, where quadriplegia is defined as having very limited or no hand, wrist, and arm movement and all levels below

Life expectancy ≥ 12 months.

Ability to communicate in English

Presence of a stable caregiver

Disqualifiers

Moderate to high risk for serious perioperative adverse events

Active implanted devices

Morbid obesity (Body Mass Index > 40)

History of poorly controlled seizures or epilepsy

Trial design

Treatments tested in this trial

  • N1 Implant
  • R1 Robot

Treatment groups

15 Participants
are divided into 1 treatment group

Sponsors and collaborators